Alzamend Neuro, Inc. (ALZN) stock
ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
$1.04−0.09 (-7.96%)
Close on Nov 18, 2026Market cap $5.02MP/E –Yield –
Alzamend Neuro operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alzamend Neuro's operating income for the twelve months ending Jul 31, 2026 was -$9.09M. For fiscal 2026 it was -$8.77M. The highest annual figure on record is -$4.42M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$8.77M | – |
| FY2025 | Apr 30, 2025 | -$4.50M | – |
| FY2024 | Apr 30, 2024 | -$9.94M | – |
| FY2023 | Apr 30, 2023 | -$14.87M | – |
| FY2022 | Apr 30, 2022 | -$12.32M | – |
| FY2021 | Apr 30, 2021 | -$4.95M | – |
| FY2020 | Apr 30, 2020 | -$4.42M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$3.03M | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$2.87M | – |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$2.20M | – |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | -$998.11K | – |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | -$2.70M | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | -$962.41K | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$850.06K | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$2.66M | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$2.90M | – |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$3.53M | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$3.31M | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$5.42M | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -$3.11M | – |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$3.04M | – |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -$3.87M | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | -$2.56M | – |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | -$3.58M | – |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$2.31M | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$1.22M | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | -$1.12M | – |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | -$1.30M | – |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$1.32M | – |
See a number that looks wrong?